Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uterine sarcoma

C F Levenback1, G Tortolero-Luna, D K Pandey

  • 1Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA.

Obstetrics and Gynecology Clinics of North America
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complementary gene interaction and xenia effect controls the seed coat colour in interspecific cross between Trifolium alexandrinum and T. apertum.

Genetica·2019
Same author

Identification of new deep sea sinuous channels in the eastern Arabian Sea.

SpringerPlus·2016
Same author

The molecular pathology of ovarian serous borderline tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Evaluation of antioxidant, antibacterial, and antidiabetic potential of two traditional medicinal plants of India: Swertia cordata and Swertia chirayita.

Pharmacognosy research·2015
Same author

Inhibitory effect of parthenium (Parthenium hysterophorus L.) residue on growth of water hyacinth (Eichhornia crassipes mart solms.) I. Effect of leaf residue.

Journal of chemical ecology·2013
Same author

Inhibitory effect of parthenium (Parthenium hysterophorus L.) residue on growth of water hyacinth (Eichhornia crassipes Mart Solms.) II. Relative effect of flower, leaf, stem, and root residue.

Journal of chemical ecology·2013
Same journal

Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evaluation and Management of the Pediatric Gender-Diverse Patient.

Obstetrics and gynecology clinics of North America·2026
Same journal

Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

Obstetrics and gynecology clinics of North America·2026
Same journal

Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

Obstetrics and gynecology clinics of North America·2026
Same journal

Contraceptive Needs of the Transmasculine Patient.

Obstetrics and gynecology clinics of North America·2026
See all related articles

Uterine sarcomas are rare cancers with unknown causes and molecular changes. Due to their rarity, screening is not feasible, but chemoprevention may help prevent recurrence.

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Cancer Epidemiology

Background:

  • Sarcomas are rare malignant tumors with unpredictable patient outcomes.
  • Current treatment protocols for uterine sarcomas often mirror those for endometrial cancers.
  • There is a significant knowledge gap regarding the epidemiologic risk factors and molecular alterations in sarcomas.

Purpose of the Study:

  • To highlight the limited understanding of sarcoma epidemiology and molecular pathology.
  • To underscore the unsuitability of uterine sarcomas for population-based screening programs.
  • To suggest potential avenues for future research, such as chemoprevention strategies for patients at risk of recurrence or secondary malignancies.

Main Methods:

  • This study is a review and synthesis of existing knowledge on uterine sarcomas.

Related Experiment Videos

  • It critically evaluates the current literature on sarcoma epidemiology and molecular characteristics.
  • It discusses the implications of tumor rarity for clinical research and patient management.

    • Main Results:

    • Epidemiologic risk factors for sarcomas remain largely uncharacterized.
    • Molecular alterations in sarcomas have not been extensively studied.
    • The rarity of uterine sarcomas precludes their inclusion in screening initiatives.

    Conclusions:

    • Further research is needed to elucidate the epidemiologic and molecular underpinnings of sarcomas.
    • Screening is not a viable strategy for uterine sarcomas due to their low incidence.
    • Chemoprevention represents a potential therapeutic strategy for managing sarcoma recurrence and preventing secondary cancers.